Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) Insider Sells 40,468 Shares of Stock

BeiGene, Ltd. (NASDAQ:BGNE) insider Xiaodong Wang sold 40,468 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $190.10, for a total value of $7,692,966.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

BeiGene Stock Up 4.3 %

BGNE stock opened at $215.00 on Friday. The firm’s fifty day moving average is $212.42 and its 200 day moving average is $184.63. The firm has a market cap of $20.94 billion, a PE ratio of -26.09 and a beta of 0.63. BeiGene, Ltd. has a one year low of $126.97 and a one year high of $248.16. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business’s revenue for the quarter was up 28.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.01 EPS. On average, research analysts forecast that BeiGene, Ltd. will post -5.38 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on BGNE. JPMorgan Chase & Co. boosted their price target on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, October 22nd. TD Cowen increased their price target on shares of BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Citigroup lifted their price objective on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. JMP Securities initiated coverage on shares of BeiGene in a research note on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price objective on the stock. Finally, StockNews.com downgraded shares of BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $247.07.

Institutional Investors Weigh In On BeiGene

Several institutional investors and hedge funds have recently added to or reduced their stakes in BGNE. XTX Topco Ltd acquired a new stake in shares of BeiGene in the third quarter valued at about $1,614,000. Quantinno Capital Management LP purchased a new position in BeiGene in the 3rd quarter valued at about $295,000. Point72 Asset Management L.P. boosted its holdings in BeiGene by 74.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 667,166 shares of the company’s stock worth $149,785,000 after buying an additional 285,784 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in BeiGene during the 3rd quarter worth approximately $67,000. Finally, Erste Asset Management GmbH acquired a new position in shares of BeiGene during the third quarter valued at approximately $4,478,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.